New drug combo shows promise in slowing advanced breast cancer

NCT ID NCT01992952

Ongoing Disease control Sponsor: Velindre NHS Trust Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a targeted drug called AZD5363 to the standard hormone therapy fulvestrant can slow the growth of advanced estrogen-receptor-positive (ER+) breast cancer. It involves 149 postmenopausal women whose cancer has worsened despite prior treatment with an aromatase inhibitor. The trial has two phases: first finding the safest dose, then comparing the combination against fulvestrant alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD5363 (a targeted drug) combined with fulvestrant (a hormone therapy)
What this could lead to: If it works, this could offer a new treatment option that delays cancer progression for postmenopausal women with advanced ER+ breast cancer.
What could go wrong: This is an early-phase trial (1b/2) with a small number of participants, so results may not confirm benefit. The drug combination may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast carcinoma estrogen-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER

Contacts and locations

Locations

Blackpool Victoria Hospital

Blackpool, United Kingdom
Calderdale and Huddersfield NHS Foundation Trust

Huddersfield, United Kingdom
Christie Hospital

Manchester, Greater Manchester, United Kingdom
Clatterbridge Cancer Centre

Bebington, United Kingdom
Derriford Hospital

Plymouth, United Kingdom
Glan Clwyd Hospital

Rhyl, United Kingdom
Great Western General Hospital

Edinburgh, United Kingdom
Mount Vernon Cancer Centre

London, United Kingdom
Queen's Hospital

Romford, United Kingdom
Royal Albert and Edward Infirmary -Wrightington

Wigan, United Kingdom
Royal Blackburn Hospital

Blackburn, United Kingdom
Royal Free Hospital

London, United Kingdom
Royal Preston Hospital

Preston, United Kingdom
Royal Stoke University Hospital

Stoke-on-Trent, United Kingdom
Southampton General Hospital

Southampton, United Kingdom
St James's University Hospital

Leeds, United Kingdom
The Ipswich Hospital NHS Trust

Ipswich, United Kingdom
University Hospital of North Durham

Durham, United Kingdom
University Hospitals Morecambe Bay

Lancaster, United Kingdom
Velindre NHS Trust

Cardiff, Cardiff, United Kingdom
Ysbyty Gwynedd

Bangor, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.